Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data

Published:2021-01-01 Issue:1 Volume:10 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Dudnik Elizabeth¹²^ORCID,Moskovitz Mor³,Rottenberg Yakir⁴⁵,Lobachov Anastasiya⁶,Mandelboim Rinat¹,Shochat Tzippy⁷,Urban Damien²⁶,Wollner Mira³,Nechushtan Hovav⁴⁵,Rotem Ofer¹,Zer Alona¹²,Daher Sameh⁶,Bar Jair²⁶,

Affiliation:

1. Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel

2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

3. Oncology Department, Thoracic Cancer Service, Rambam Health Care Campus, Haifa, Israel

4. Oncology Department, Hadassah Medical Center, Jerusalem, Israel

5. Hebrew University of Jerusalem, Hadassah Medical Center, Jerusalem, Israel

6. Thoracic Cancer Service, Institute of Oncology, Sheba Medical Center, Ramat Gan, Israel

7. Statistical Consulting Unit, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel

Funder

public, commercial, or not-for-profit sectors

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2020.1865653

Reference33 articles.

1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

2. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

4. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

5. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pembrolizumab monotherapy survival benefits in metastatic non-small-cell lung cancer: a systematic review of real-world data;Discover Oncology;2024-07-24

2. Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD‐L1 expression: Updated analysis;Cancer Medicine;2024-07

3. Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study);Cancers;2024-05-08

4. Real-world comparative effectiveness and safety of pembrolizumab for PD-L1≥50% metastatic non-small-cell lung cancer;FUTURE ONCOL;2024

5. Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma;International Immunopharmacology;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3